Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Turn Therapeutics Inc. - Common Stock
(NQ:
TTRX
)
8.940
-0.860 (-8.78%)
Delayed Quote
Updated: 4:00 PM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Turn Therapeutics Inc. - Common Stock
Turn Therapeutics’ GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program
November 05, 2026
From
Turn Therapeutics
Via
Business Wire
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
October 21, 2026
From
Turn Therapeutics Inc.
Via
Business Wire
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
September 10, 2026
From
Turn Therapeutics Inc.
Via
Business Wire
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
September 09, 2026
From
Turn Therapeutics, Inc.
Via
Business Wire
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
August 20, 2026
From
Turn Therapeutics Inc.
Via
Business Wire
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
August 12, 2026
From
Turn Therapeutics Inc.
Via
Business Wire
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
July 28, 2026
From
Turn Therapeutics Inc.
Via
Business Wire
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
July 07, 2026
From
Turn Therapeutics, Inc.
Via
Business Wire
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
July 06, 2026
From
Turn Therapeutics, Inc.
Via
Business Wire
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
June 01, 2026
From
Turn Therapeutics Inc.
Via
Business Wire
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
May 27, 2026
From
Turn Therapeutics Inc.
Via
Business Wire
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
May 19, 2026
From
Turn Therapeutics Inc.
Via
Business Wire
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
May 18, 2026
From
Turn Therapeutics Inc.
Via
Business Wire
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 11, 2026
From
Turn Therapeutics Inc.
Via
Business Wire
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
March 31, 2026
From
Turn Therapeutics Inc.
Via
Business Wire
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
March 24, 2026
From
Turn Therapeutics, Inc.
Via
Business Wire
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
February 17, 2026
From
Turn Therapeutics, Inc.
Via
Business Wire
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
February 09, 2026
From
Turn Therapeutics Inc.
Via
Business Wire
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From
Turn Therapeutics, Inc.
Via
Business Wire
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
January 07, 2026
Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic Long-Term Goals for Growth and Expansion
From
Turn Therapeutics
Via
GlobeNewswire
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 13, 2025
From
Turn Therapeutics
Via
GlobeNewswire
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
November 11, 2025
Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar Therapeutics
From
Turn Therapeutics
Via
GlobeNewswire
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
November 11, 2025
Conversation Centered Around Healthcare Communications and Pandemic Preparedness
From
Turn Therapeutics
Via
GlobeNewswire
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
November 04, 2025
From
Turn Therapeutics
Via
GlobeNewswire
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
October 30, 2025
Agreement combines Turn’s PermaFusion® delivery platform with Medline’s global scale and distribution capabilities to advance professional and retail product opportunities
From
Turn Therapeutics
Via
GlobeNewswire
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
October 22, 2025
Company to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategy
From
Turn Therapeutics
Via
GlobeNewswire
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
October 20, 2025
From
Turn Therapeutics
Via
GlobeNewswire
Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors
October 15, 2025
Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease research
From
Turn Therapeutics
Via
GlobeNewswire
Turn Therapeutics Appoints Arthur Golden to Board of Directors
October 14, 2025
Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs
From
Turn Therapeutics
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
